Predictors of prognosis in patients with stable mild to moderate heart failure

Bettencourt, Paulo; Ferreira, António; Dias, Paula; Pimenta, Joana; Friões, Fernando; Martins, Leopoldo Henrique Barboza; Cerqueira-Gomes, M

doi:10.1054/jcaf.2000.20558

Cited by 108 publications

(80 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Independent risk factors for mortality in Japanese HF patients: Several factors are considered to affect the mortality of HF patients, including older age, severity of HF, 12,27) anemia, presence of CKD, [28][29][30][31][32] higher BNP, 33,34) and lower LVEF. 35) In the present study, all of these clinical variables were determined to be significant risk factors for mortality in univariate analysis. Recently, multivariate analysis using populations from randomized treatment trials or populationbased studies performed in Western countries showed that CKD was significantly associated with a poor prognosis of patients with HF as an independent risk factor.…”

Section: Discussionmentioning

confidence: 90%

Prevalence and Prognosis of Patients With Heart Failure in Tokyo

et al. 2009

View full text Add to dashboard Cite

SummaryPrognosis of patients with heart failure (HF) remains unclear in Japan and should be determined in a prospective fashion. A prospective cohort of The Shinken Database comprised details on all of the new patients, including both inpatients and outpatients, who visited The Cardiovascular Institute Hospital in [2004][2005]. HF patients were defined as those with symptomatic HF coexisting with structural heart diseases. Among 4,255 patients who visited our hospital, 597 patients (male/female 414/183, age 65.1 ± 12.9 years, LVEF 56.2 ± 18.0%) were diagnosed as presenting symptomatic HF. Ischemic heart disease was present in 305 (51.1%), valvular heart disease in 212 (35.5%), dilated cardiomyopathy in 59 (9.9%), hypertrophic cardiomyopathy in 24 (4.0%), hypertensive heart disease in 14 (2.3%), and others in 67 (11.2%). Hypertension, atrial fibrillation, and diabetes were observed in 35.3%, 27.4%, and 23.7%, respectively. During the mean follow-up period of 539 ± 257 days, 40 deaths (5.0% per year) occurred, including 34 cardiovascular deaths (4.5% per year, NYHA class II: 1.0%, III: 11.3%, IV: 36.6% per year, respectively). The present study showed that the prognosis of Japanese patients with HF among moderate to severe severity was found to be similar to that of Western countries. Multiple Cox hazard analysis identified the presence of chronic kidney disease and NYHA class as independent predictors for cardiovascular death. This prospective cohort study identified the prevalence, prognosis, and risk factors in HF patients to provide a basis for therapeutic management in Japan. (Int Heart J 2009; 50: 609-625)

show abstract

Section: Discussionmentioning

confidence: 90%

Prevalence and Prognosis of Patients With Heart Failure in Tokyo

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The role of cardiac biomarkers in the evaluation and risk stratification of patients presenting to the hospital with possible heart failure continues to increase in importance (2). Biomarkers can serve to confirm the diagnosis in symptomatic patients, help in the assessment of patients who present with nonspecific symptoms, and evaluate prognosis of patients.…”

Section: Introductionmentioning

confidence: 99%

Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels

Takeishi

Toriyama²,

Takabatake

et al. 2007

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

show abstract

“…The use of non invasive cardiopulmonary gas exchange testing has expanded into a number of clinical areas and is now used frequently to characterize disease status, determine response to therapy and gain perspective on prognosis [1,3,[16][17][18][19][20]. Limitations to further expansion of this testing to other clinical areas include space requirements, adequately trained personnel, the complexity and time for testing as well as the significant costs.…”

Section: Benefits Of Submaximal Cardiopulmonary Exercise Testingmentioning

confidence: 99%

“…Cardiopulmonary exercise testing is playing an expanding role in the management of a variety of clinical populations, including heart failure, pulmonary hypertension, obstructive and restrictive lung disease [1]. Traditionally, non invasive measures of gas exchange have focused on determination of peak oxygen consumption (VO 2peak ), however, it is becoming increasingly clear that many submaximally determined gas exchange parameters (e.g., ventilatory efficiency -V E /VCO 2 , end tidal CO 2 -PetCO 2 , oxygen efficiency slope) may be as important as peak variables for quantifying health status, determining prognosis, as well as following response to therapy [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Validation of a Simplified, Portable Cardiopulmonary Gas Exchange System for Submaximal Exercise Testing~!2009-10-25~!2010-01-09~!2010-03-17~!

Miller¹,

Woods²,

Olson³

et al. 2010

TOSMJ

View full text Add to dashboard Cite

Shape Medical Systems, Inc. has developed a new miniaturized, simplified system for non-invasive cardiopulmonary gas exchange quantification and has targeted their system for submaximal clinical exercise testing in order to abbreviate testing in an expanding clinical market during a climate of escalating health care costs. The focus of the present study was to compare this new device to a validated, standardized system for measures of cardiopulmonary gas exchange. Eighteen healthy adults (10 male/8 female, age 29±7 yr, BMI 23.8±2.4 kg/m 2 ) were brought to the laboratory and instrumented with both measurement systems via in-series pneumotachs. Additionally, the Shape system included a pulse oximeter for heart rate (HR) and oxygen saturation (SaO 2 ), while the standard system included separate 12-lead ECG and oximetry devices. The protocol included 2-min resting breathing, followed by 3-min at each of 3 workloads (50, 70, 125 watts) on a cycle ergometer. Data were collected breath-by-breath and averaged the last 30-sec of each workload. After a 15-min rest period, the pneumotach order was reversed and the study repeated. Since gas exchange data were similar (p>0.05) within a given metabolic testing system between sessions the data were pooled for comparing the Shape and Standard systems. There were no differences (p>0.05) between the systems for oxygen consumption-VO 2 , carbon dioxide production-VCO 2 , ventilation-V E , end tidal CO 2 -PetCO 2 , tidal volume-V T , respiratory rate-fb, and HR at rest or any work load. SaO 2 was slightly, but significantly lower using the Shape embedded oximeter (p<0.05, averaging ~1% across workloads). There were significant correlation coefficients (p<0.001) between the systems for VO 2 (r=0.991), VCO 2 (r=0.986), V E (r=0.995) and PetCO 2 (r=0.953). Bland Altman plots indicated good agreement between systems for the same gas exchange measures, independent of workload. The Shape system was sensitive to small increases in work (50 to 70 watts) and there were no differences in gas exchange measures in a subgroup of subjects (n=4) using a tight fitting mask instead of a mouthpiece (p>0.05). These data suggest that the new, simplified metabolic system developed by Shape Medical Systems, Inc. accurately quantifies key cardiopulmonary variables over a range of workloads, has a coefficient of variation similar to a well validated system and can be used with mouthpiece or mask.

show abstract

Predictors of prognosis in patients with stable mild to moderate heart failure

Cited by 108 publications

References 32 publications

Prevalence and Prognosis of Patients With Heart Failure in Tokyo

Prevalence and Prognosis of Patients With Heart Failure in Tokyo

Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels

Validation of a Simplified, Portable Cardiopulmonary Gas Exchange System for Submaximal Exercise Testing~!2009-10-25~!2010-01-09~!2010-03-17~!

Contact Info

Product

Resources

About